anti-EX02 CAR T cells

Phase 1Cell therapy

ZZhang Xiaofeng,MD

anti-EX02 CAR T cells is one of 7 small molecule programs targeting Bile Duct Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bile Duct CancerNot yet recruiting

Bile Duct CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Bile Duct Cancer

#DrugCompanyPhaseTrials

Stivarga

Ixempra

Photofrin

PPinnacle Biologics Inc.

Approved

—4

Photosensitizer

UUniversity of Leipzig

Phase 3

1 5

Tecentriq

Roche

Preclinical

1 6

Fotivda

AAVEO Pharmaceuticals, Inc.

Preclinical

1 7

anti-EX02 CAR T cells

ZZhang Xiaofeng,MD

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Bile Duct Cancer

NCT06196658

Clinical

Trials by Indication[1]

Bile Duct Cancer1 trial

Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer

Not yet recruiting·ZZhang Xiaofeng,MD·Phase 1·NCT06196658·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for anti-EX02 CAR T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti-EX02 CAR T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti-EX02 CAR T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhang Xiaofeng,MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: ZZhang Xiaofeng,MD

anti-EX02 CAR T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Bile Duct Cancer1 trial

References

Drug Info

Quick Facts

Related News